FUSED IMIDAZOLIUM DERIVATIVES

摘要

This invention relates to medicaments, particularly novel fused imidazolium derivatives useful for the treatment of cancers and novel synthetic intermediate compounds thereof having the formula: <IMG> The novel imidazolium derivatives fused with an aryl ring or heteroaryl ring, characterized in that the 1- and/or 3-position is substituted by an alkyl group etc. having a substituent selected from the group consisting of -OR a, -SR a, -prodrug-formed OH, -O-lower alkylene-OR a, -O-lower alkylene-O-lower alkylene-OR a, -O-lower alkylene-NR a R b, -O-lower alkylene-O-lower alkylene-NR a R b, -O-lower alkylene-NR c-lower alkylene-NR a R b, -OCO-NR a R b, -SOR a, -SO2R a, -SO2NR a R b, -NR a-SO2R b, -CO2H, -NR a R b, -NR c-lower alkylene-NR a R b, -N (-lower alkylene- NR a R b)2r, -RinD, -NO2, -CN, -halogen, -CO2R a, -COO-, -CONR a R b, -CONR a-O-R b, -NR a-COR b, -NR a-CO-NR b R c, -OCOR a and -CO-R a, have excellent anti-tumor activity and low toxicity and are useful as anticancer agents having wide margins of safety.